Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Brief description of study
This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.
The study will evaluate safety, tolerability, and pharmacokinetics of NUV-868, a BD-2 selective inhibitor of BRD4 as monotherapy and in combination with olaparib or enzalutamide and evaluate antitumor activity in advanced solid tumors.
Clinical Study Identifier: s22-01098
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
